Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Cheng, Zhuzhong; Wei, Renbo; Wu, Changqiang; Qing, Haomiao; Jiang, Xiao; Lu, Hao; Chen, Shirong; Li, Xinping; Xu, Guohui; Ai, Hua
• Is Part Of: Nuclear medicine communications. Volume 36:Issue 9(2015:Sep.)
• Publication Date: 2015-09
• Subjects: Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000000339
• Languages: English
• ISSNs: 0143-3636

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Objective</title> <p> <sup>18</sup>F-Fluorodeoxyglucose (<sup>18</sup>F-FDG), <sup>18</sup>F-fluoro-3′-deoxy-3′-L-fluorothymidine (<sup>18</sup>F-FLT), <sup>18</sup>F-fluoromisonidazole (<sup>18</sup>F-FMISO), and <sup>18</sup>F-AlF-NOTA-PRGD2 (<sup>18</sup>F-RGD) are all commonly used PET tracers for tumor diagnosis based on different mechanisms of tissue uptake. This study compared the ex-vivo biodistribution and PET/computed tomography (CT) imaging studies of these four PET tracers in a xenograft prostate tumor-bearing mouse model.</p> </sec> <sec> <title>Materials and methods</title> <p>Nude mice were inoculated with 5×10<sup>6</sup> PC-3 cells in the right armpit. The ex-vivo biodistribution of <sup>18</sup>F-FDG, <sup>18</sup>F-FLT, <sup>18</sup>F-FMISO, and <sup>18</sup>F-RGD at 30, 60, 90, and 120 min after injection was compared. Micro-PET/CT images of <sup>18</sup>F-FDG, <sup>18</sup>F-FLT, and <sup>18</sup>F-RGD were acquired at 60 min, whereas <sup>18</sup>F-FMISO images were acquired at 90 min after injection.</p> </sec> <sec> <title>Results</title> <p>The tumors were clearly visualized by micro-PET/CT using all four PET tracers. Ex-vivo biodistribution results showed highest tumor accumulation and tumor-to-muscle ratio of <sup>18</sup>F-FDG at each time point, accompanied by physiologically high uptakes in the brain, heart, and intestinal tract. Modest uptake of <sup>18</sup>F-FLT and <sup>18</sup>F-FMISO in tumors was observed at 60 and 90 min after injection, with less interference from other tissues compared with <sup>18</sup>F-FDG. Besides, <sup>18</sup>F-RGD also exhibited high tumor specificity; however, relatively low uptake was observed in the tumor.</p> </sec> <sec> <title>Conclusion</title> <p>Our results demonstrated the potential of <sup>18</sup>F-FMISO and <sup>18</sup>F-FLT in the diagnosis of xenograft prostate cancer.</p> </sec> </abstract>